Alendronate and naproxen are synergistic for development of gastric ulcers
- PMID: 11146706
- DOI: 10.1001/archinte.161.1.107
Alendronate and naproxen are synergistic for development of gastric ulcers
Erratum in
- Arch Intern Med 2001 Aug 13-27;161(15):1862
Abstract
Background: Both alendronate sodium use and nonsteroidal anti-inflammatory drug use are associated with gastric ulcers. The aim of this study was to investigate whether alendronate and naproxen are synergistic as causes of gastric ulcers.
Methods: We performed an endoscopist-blind, randomized, crossover, single-center comparison of 10 mg/d of alendronate sodium, 500 mg of naproxen sodium twice daily, or the combination taken orally for 10 days in volunteers aged 30 years or older. Videoendoscopy was used to evaluate the presence and degree of mucosal damage to the esophagus, stomach, or duodenal bulb before and after each treatment. There was a 1- to 4-week washout between evaluations.
Results: Twenty-six healthy volunteers participated (18 women and 8 men), aged 30 to 50 years. Gastric ulcers were present in 2 subjects receiving alendronate (8%), in 3 receiving naproxen (12%), and in 10 receiving both (38%) (P<.05 for the combination vs either drug alone).
Conclusions: Both alendronate and naproxen can cause gastric ulcers. The combination appears synergistic. Alendronate should be used with caution in those who simultaneously require nonsteroidal anti-inflammatory drugs.
Similar articles
-
Risk of ulcer soars with combination of arthritis drugs.West J Med. 2001 Apr;174(4):236. doi: 10.1136/ewjm.174.4.236. West J Med. 2001. PMID: 11290669 Free PMC article. Clinical Trial. No abstract available.
-
Alendronate gastric ulcers.Aliment Pharmacol Ther. 1999 Apr;13(4):515-9. doi: 10.1046/j.1365-2036.1999.00488.x. Aliment Pharmacol Ther. 1999. PMID: 10215737 Clinical Trial.
-
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.Clin Ther. 2006 Mar;28(3):340-51. doi: 10.1016/j.clinthera.2006.03.007. Clin Ther. 2006. PMID: 16750449 Clinical Trial.
-
Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs.Dig Dis. 1995 Jan;13 Suppl 1:48-61. doi: 10.1159/000171526. Dig Dis. 1995. PMID: 7697902 Review.
-
NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.Dig Liver Dis. 2007 Dec;39(12):1043-51. doi: 10.1016/j.dld.2007.09.001. Epub 2007 Nov 7. Dig Liver Dis. 2007. PMID: 17997373 Review.
Cited by
-
Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy.J Gastroenterol. 2009;44(2):113-20. doi: 10.1007/s00535-008-2278-2. Epub 2009 Feb 13. J Gastroenterol. 2009. PMID: 19214672
-
Clodronic acid formulations available in Europe and their use in osteoporosis: a review.Clin Drug Investig. 2009;29(6):359-79. doi: 10.2165/00044011-200929060-00001. Clin Drug Investig. 2009. PMID: 19432497 Review.
-
Bisphosphonates and risk of cancers: a systematic review and meta-analysis.Br J Cancer. 2020 Nov;123(10):1570-1581. doi: 10.1038/s41416-020-01043-9. Epub 2020 Sep 9. Br J Cancer. 2020. PMID: 32901134 Free PMC article.
-
Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.Dig Dis Sci. 2010 Dec;55(12):3404-7. doi: 10.1007/s10620-010-1198-1. Epub 2010 Apr 16. Dig Dis Sci. 2010. PMID: 20397052
-
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.Drugs. 2006;66(10):1351-9. doi: 10.2165/00003495-200666100-00004. Drugs. 2006. PMID: 16903769 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources